QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Tecan Group AG (SIX Swiss Exchange: TECN), a global leader in laboratory automation and liquid handling technology, announced today a collaboration to improve the processing of QIAGENs QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the utilization of Tecans Fluent Laboratory Automation workstation for the aliquoting of samples for the optional Lithium Heparin single-tube workflow. The Fluent instruments will be supplied directly to laboratories through Tecans Life Sciences Business.

QIAGENs fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection based on world leading interferon gamma release assay (IGRA) technology.

QuantiFERON-TB Gold Plus offers customers the most flexible workflow among latent TB screening tests, including a single-tube option that enables efficient screening in large-scale programs by collecting blood samples at patient sites and transporting them to labs for processing up to 53 hours after venipuncture.

The two parties are working together to optimize a solution that standardizes and automates the manual steps in liquid handling for the aliquoting of samples. Customers will be able to leverage the high-performance Fluent automation system and thereby achieve the goal of significantly reducing hands-on time, providing greater ease of use and ensure consistency in pre-analytic methods and thereby reducing processing errors and variability between runs. Front-end automation solutions also offer laboratories efficient automation of single tube collection for QuantiFERON, and thereby create efficiency in the lab and improve the patient blood collection experience.

Please find the full press release here

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

###

Investor Relations
John Gilardi
+49 2103 29 11711

Dr.
Sarah Fakih
+49 2103 29 11457
e-mail: [email protected]

Public
Relations

Dr. Thomas Theuringer
+49 2103 29 11826

Robert
Reitze
+49 2103 29 11676
e-mail: [email protected]

Tecan
Group

Martin Braendle
Vice President, Communications &
Investor Relations
Tel. +41 (0) 44 922 84 30
email: [email protected]
www.tecan.com